News

Amgen’s Tepezza becomes first U.K.-medicine approved for adults with thyroid eye disease
The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...
Fierce Pharma8d
As Amgen's trio of Horizon drugs disappoints, execs urge analysts to give them more time
It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...
Ophthalmology Times7d
EMA CHMP issues positive opinion for teprotumumab (Tepezza) marketing authorization application
In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.
PharmaTimes2d
Amgen’s Tepezza granted marketing authorisation in the UK
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...
The Pharma Letter2d
MHRA approves Amgen’s Tepezza for TED
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...
National Health Executive1d
UK first treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...
Medscape10d
EMA Recommends Tepezza for Severe Thyroid Eye Disease
The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with ...
The Pharma Letter2d
MHRA approves Amgen’s Tepezza for NED
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...
PharmaTimes2d
Amgen’s Tepezza granted marketing authorisation in the UK
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza (teprotumumab) as the first licensed treatment for adults with ...
Seeking Alpha3d
Amgen’s Tepezza becomes first U.K.-medicine approved for adults with thyroid eye disease
The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the country’s medicine indicated specifically for adults with moderate to ...